Importantly, the knockdown of TBX2 promoted sensitivity to cisplatin in breast cancer and melanoma, to temozolomide in GBM, to carboplatin in ovarian serous carcinoma and to androgen deprivation therapy in advanced prostate cancer [17–19,37]. Here, TBX2 is linked to melanoma.